Gail B. Cross

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

thelancet.com Favicon

Articles

PET-CT outcomes from a randomised controlled trial of rosuvastatin as an adjunct to standard tuberculosis treatment - Nature Communications

Dec 1, 2024 | nature.com | Gail B. Cross |Intan P Sari |Han Nguyen |Christina C. Chang |Anthony D. Kelleher |Jim O’Doherty

AbstractAdjunctive rosuvastatin for rifampicin-susceptible pulmonary tuberculosis (rs-PTB) shows no effect on microbiological or radiological outcomes in a phase IIb randomised, controlled trial (NCT04504851). We explore the impact of adjunctive rosuvastatin on 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) imaging in a sub-study of 24 participants.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →